Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Sprycel pricing

Executive Summary

Bristol-Myers Squibb is positioning its chronic myeloid leukemia therapy Sprycel (dasatinib) as a less expensive option than high-dose Gleevec (imatinib) for second-line use in Gleevec failures. Sprycel became available within days of its June 28 accelerated approval at a price of $3,900 for a month of treatment at the recommended dosage of 140 mg/day, according to Bristol (1"The Pink Sheet" July 3, 2006, p. 5). In clinical trials, median duration of dasatinib therapy ranged from 2.8 months for lymphoid blast to 5.6 months for CML; the CML trial is ongoing. The company is detailing its multiple tyrosine kinase inhibitor to oncologists and hematologists; the oncology sales force, which has fewer than 200 reps, also details Erbitux (cetuximab)...

You may also be interested in...



Bristol Sprycel Clears FDA As First Second-Line Leukemia Agent

Bristol-Myers Squibb will be required to submit follow-up data from ongoing clinical trials to convert the accelerated approval of Sprycel for chronic myeloid leukemia to full approval, FDA said after clearing dasatinib June 28

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials

To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.

UsernamePublicRestriction

Register

LL1135972

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel